GKM 001
Alternative Names: ADV-1002401; GKM-001Latest Information Update: 15 Apr 2026
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 15 Apr 2026 Phase I development is ongoing in Type-2 diabetes mellitus in India (Impetis Biosciences pipeline, April 2026)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in India (PO, Tablet)
- 30 Dec 2022 GKM 001 is still in phase I clinical development in Type 2 diabetes mellitus in India (PO) (Impetis Biosciences pipeline, December 2022)